blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2755640

EP2755640 - TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.06.2018
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  23.06.2017
FormerGrant of patent is intended
Status updated on  12.02.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Purdue Pharma LP
One Stamford Forum 201 Tresser Boulevard
Stamford, CT 06901-3431 / US
[2014/30]
Inventor(s)01 / MCKENNA, William
10 Longmeadow Road
Yonkers, NY 10704 / US
02 / MULEY, Sheetal, R.
145 Mountain Avenue
Piscataway, NJ 08854 / US
03 / ABU SHMEIS, Rama
13 Buffalo Hollow Road
Branchburg, NJ 08876 / US
 [2014/30]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2014/30]Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date12813950.814.09.2012
[2017/30]
WO2012IB01914
Priority number, dateUS201161535743P16.09.2011         Original published format: US 201161535743 P
[2014/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013038267
Date:21.03.2013
Language:EN
[2013/12]
Type: A1 Application with search report 
No.:EP2755640
Date:23.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 21.03.2013 takes the place of the publication of the European patent application.
[2014/30]
Type: B1 Patent specification 
No.:EP2755640
Date:26.07.2017
Language:EN
[2017/30]
Search report(s)International search report - published on:EP21.03.2013
ClassificationIPC:A61K9/16, A61K31/485, A61K9/20, A61K9/48
[2017/07]
CPC:
A61K31/485 (EP,US); A61K9/1635 (EP,US); A61K9/1641 (EP,US);
A61K9/1652 (EP,US); A61K9/2031 (EP,US); A61K9/2054 (EP,US);
A61K9/2077 (EP,US); A61K9/4808 (EP,US); A61P25/04 (EP);
A61P25/36 (EP); A61K9/1682 (EP,US) (-)
Former IPC [2014/30]A61K9/20, A61K9/28, A61K31/485
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/30]
Extension statesBA31.03.2014
ME31.03.2014
TitleGerman:MANIPULATIONSSICHERE PHARMAZEUTISCHE FORMULIERUNGEN[2014/30]
English:TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS[2014/30]
French:FORMULATIONS PHARMACEUTIQUES INVIOLABLES[2014/30]
Entry into regional phase31.03.2014National basic fee paid 
31.03.2014Designation fee(s) paid 
31.03.2014Examination fee paid 
Examination procedure31.03.2014Examination requested  [2014/30]
25.11.2014Amendment by applicant (claims and/or description)
17.02.2015Despatch of a communication from the examining division (Time limit: M06)
25.09.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
02.12.2015Reply to a communication from the examining division
15.02.2016Despatch of a communication from the examining division (Time limit: M04)
23.06.2016Reply to a communication from the examining division
05.09.2016Despatch of a communication from the examining division (Time limit: M02)
26.10.2016Reply to a communication from the examining division
13.02.2017Communication of intention to grant the patent
13.06.2017Fee for grant paid
13.06.2017Fee for publishing/printing paid
13.06.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.02.2015
Opposition(s)30.04.2018No opposition filed within time limit [2018/27]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
02.12.2015Request for further processing filed
02.12.2015Full payment received (date of receipt of payment)
Request granted
14.12.2015Decision despatched
Fees paidRenewal fee
08.09.2014Renewal fee patent year 03
08.09.2015Renewal fee patent year 04
08.09.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.09.2012
AL26.07.2017
AT26.07.2017
CY26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
MK26.07.2017
PL26.07.2017
PT26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
TR26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
[2020/34]
Former [2020/28]HU14.09.2012
AT26.07.2017
CY26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
MK26.07.2017
PL26.07.2017
PT26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
TR26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2020/15]HU14.09.2012
AT26.07.2017
CY26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
MK26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
TR26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2019/51]HU14.09.2012
AT26.07.2017
CY26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
MK26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2019/46]HU14.09.2012
AT26.07.2017
CY26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2019/31]HU14.09.2012
AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/43]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
MT14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/39]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SI26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
BE30.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/34]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SK26.07.2017
SM26.07.2017
IE14.09.2017
LU14.09.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/26]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
MC26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SK26.07.2017
SM26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/24]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SK26.07.2017
SM26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/23]AT26.07.2017
CZ26.07.2017
DK26.07.2017
EE26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
PL26.07.2017
RO26.07.2017
RS26.07.2017
SE26.07.2017
SK26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/21]AT26.07.2017
CZ26.07.2017
DK26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
PL26.07.2017
RS26.07.2017
SE26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/12]AT26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
LV26.07.2017
PL26.07.2017
RS26.07.2017
SE26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/11]AT26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
PL26.07.2017
RS26.07.2017
SE26.07.2017
BG26.10.2017
NO26.10.2017
GR27.10.2017
IS26.11.2017
Former [2018/10]AT26.07.2017
FI26.07.2017
HR26.07.2017
LT26.07.2017
RS26.07.2017
SE26.07.2017
NO26.10.2017
Former [2018/09]FI26.07.2017
LT26.07.2017
SE26.07.2017
NO26.10.2017
Former [2018/08]FI26.07.2017
LT26.07.2017
NO26.10.2017
Former [2018/07]LT26.07.2017
NO26.10.2017
Cited inInternational search[X]US2005031546  (BARTHOLOMAUS JOHANNES [DE], et al) [X] 1-121 * examples 1-6 *;
 [X]WO2006058249  (ACURA PHARMACEUTICALS INC [US], et al) [X] 1-121 * examples 1-47 *;
 [X]EP1897545  (PURDUE PHARMA LP [US]) [X] 1-121 * examples 1-31 *;
 [X]US2008063725  (GUIMBERTEAU FLORENCE [FR], et al) [X] 1-121 * examples 6,8-10,12 *;
 [X]US2008152595  (EMIGH JAMES F [US], et al) [X] 1-121 * examples 1-47; claims 1-47 *;
 [X]US2009022798  (ROSENBERG JOERG [DE], et al) [X] 1-121 * tables 1-38 *;
 [X]WO2009025859  (TEVA PHARMA [IL], et al) [X] 1-121 * examples 1-4,8-12 *;
 [XP]WO2012085656  (PURDUE PHARMA LP [US], et al) [XP] 1-121* the whole document *
ExaminationUS2008254112
by applicantWO2005097801
 US2006173029
 US7129248
 US2009081290
    - "Oral Solid Dosage Forms", Remington's Pharmaceutical Sciences, 18th edition,, (1990), pages 1633 - 1665
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.